Imaging technologies may give answers in cancer trials
Advances in imaging technologies could provide knowledge about the pharmacodynamics and pharmacokinetics of new cancer drugs in clinical trials, according to a recent review article (Journal of the National Cancer Institute 2006;98:580).
The authors focus on two such technologies — magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) — because they are increasingly available and offer superior functional and metabolic understanding compared with many other imaging tools.
Paul Workman, lead author and chairman of Cancer Research UK’s pharmacodynamic and pharmacokinetic technologies advisory committee, said that technologies such as MRS and PET could improve how drugs are monitored and reduce the need for invasive procedures such as biopsies.
Citation: The Pharmaceutical Journal URI: 10021706
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now